OTLK
NASDAQOutlook Therapeutics Inc.
Price$0.49-0.03 (-6.29%)
01:30 PM07:45 PM
News · 26 weeks74-44%
2026-04-192026-10-11
Mix3990d
- SEC Filings13(33%)
- Other12(31%)
- Insider8(21%)
- Offering3(8%)
- Leadership2(5%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Outlook Therapeutics Inc.SCHEDULE 13G - Outlook Therapeutics, Inc. (0001649989) (Subject)
- PROutlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced Greg DiPasquale as Chief Commercial Officer. Mr. DiPasquale, who joined Outlook in December 2025 as Head of Commercial for LYTENAVA™, will lead all commercial functions as the Company prepares to make LYTENAVA, the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), available to eligible patients in the United States before the end of 2026.
- PROutlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor DiscussionSegment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™ Access the segment here ISELIN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it participated in a Virtual Investor "What This Means" segment featuring Kevin Lundquist, the Company’s recently appointed Chief Financial Officer In the discussion, Mr. Lundquist shares his perspective on joining Outlook Therapeutics
- PROutlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) Level II J-code for LYTENAVA. The submission advances Outlook Therapeutics’ U.S. comm
- SECSEC Form 8-K filed by Outlook Therapeutics Inc.8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-DemandFireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. Wainwright 28th Annual Global Investment Conference (the "Conference") is now available for on-demand viewing here. The fireside chat features Bob Jahr, Chief Executive Officer of Outlook Therapeut
- PROutlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect SegmentAccess the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S. commercial launch. During the segment, Mr. Jahr discusses the potential of LYTENAVA to address the significant U.S. retina market by providing physicians with the only FDA-approved ophthalmic formu
- INSIDERSEC Form 4 filed by Chief Financial Officer Lundquist Kevin Michael4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lundquist Kevin Michael3 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure Appointment strengthens financial and operational infrastructure as Company prepares for U.S. commercial launch following FDA approval of LYTENAVA™ ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) fo
- NEWSJTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching todayAccess on demand conference here FRENCHTOWN, NJ / ACCESS Newswire / August 27, 2026 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the release of its Virtual Investor "Why Now" On-Demand Conference, featuring a fast-paced series of 60-second presentations from the CEOs of nine publicly traded companies.The premise is simple: Why sho
- PROutlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand ConferenceVideo webcast now available here ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in the Virtual Investor "Why Now" on-demand conference. During the segment, Mr. Jahr highlighted why he believes Outlook Therapeutics is entering a transformative period following the FDA’s approval of LYTENAVA™ on July 24, 2026, making it the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD
- SECSEC Form SCHEDULE 13G filed by Outlook Therapeutics Inc.SCHEDULE 13G - Outlook Therapeutics, Inc. (0001649989) (Subject)
- SECSEC Form 10-Q filed by Outlook Therapeutics Inc.10-Q - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form NT 10-Q filed by Outlook Therapeutics Inc.NT 10-Q - Outlook Therapeutics, Inc. (0001649989) (Filer)
- INSIDERChief Executive Officer Jahr Robert Charles bought 151,515 shares (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERDirector Sukhtian Ghiath M. bought $2,499,999 worth of shares (2,525,252 units at $0.99) (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERChief Financial Officer Kenyon Lawrence A bought 101,010 shares, increasing direct ownership by 1,699% to 106,956 units (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form 424B5 filed by Outlook Therapeutics Inc.424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including broad market access, reimbursement, pricing, medical affairs, and supply capabilities Potential to exceed $500 million in annual U.S. LYTENAVA sales by 2030 Company to host corporate update conference call today, August 14th, at 8:30 AM ET — registration details below ISELIN, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab
- PROutlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and WarrantsISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to an aggregate of 55,555,556 shares of its common stock. The combined public offering price of each share of common stock and accompanying warrant to purchase one share is $0.99. The accompanying warrants have an exercise price of $1.10 per share, will become exercisabl
OTLK FAQ
7 questionsWhat does Outlook Therapeutics Inc. do?
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical...Where does OTLK stock trade?
Outlook Therapeutics Inc. (OTLK) is listed on NASDAQ.What sector and industry is OTLK in?
Outlook Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Outlook Therapeutics Inc. go public?
Outlook Therapeutics Inc. (OTLK) completed its IPO in 2016.What are analysts saying about OTLK?
Outlook Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $400.00 price target on 2026-07-27. Recent price targets range from $300.00 to $400.00.What companies are similar to OTLK?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare OTLK side-by-side with any of them on Quantisnow.How can I track OTLK on Quantisnow?
Quantisnow aggregates Outlook Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OTLK to receive live email and push alerts on every new disclosure.